A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
Status:
Completed
Trial end date:
2021-06-18
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH), Phase 1, single-center, randomized, double-blind,
placebo-controlled, single ascending dose study to evaluate the safety, tolerability, PK and
immunogenicity of AK119, a humanized monoclonal antibody targeting the CD73. The study will
consist of 4 cohorts of healthy subjects. Eight subjects will be enrolled per cohort,
randomized in a 3:1 ratio to receive a single dose of either the active drug AK119 (N=6) or
matching placebo (N=2). Approximately 32 subjects (24 receiving active drug and 8 receiving
placebo) will participate in this study.